TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
82 hedge funds and large institutions have $544M invested in TCR2 Therapeutics Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 36 increasing their positions, 12 reducing their positions, and 6 closing their positions.
300% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 6
200% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 12
132% more capital invested
Capital invested by funds: $234M → $544M (+$310M)
28% more funds holding
Funds holding: 64 → 82 (+18)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
52% less call options, than puts
Call options by funds: $708K | Put options by funds: $1.47M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$35M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$26.5M |
| 3 |
DM
Deerfield Management
New York
|
+$21.1M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$18.1M |
| 5 |
BlackRock
New York
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.39M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$2.36M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$878K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$709K |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$591K |
TCRR Hedge Fund Activity: Q3 2020 in Review
82 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q3 2020, worth a combined $544M — up 132% from $234M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new TCRR positions and 6 closed out — a net gain of 18 holders — while 36 added to existing stakes and 12 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $35M. The largest seller was Morgan Stanley, cutting an estimated $2.39M.
- 82 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q3 2020, up from 64 in Q2 2020.
- Funds reported $544M of TCR2 Therapeutics Inc. Common Stock stock for Q3 2020, up 132% quarter-over-quarter.
- 24 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q3 2020 and 6 closed out, a net change of +18 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q3 2020 was Wellington Management Group, an estimated $35M added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q3 2020 was Morgan Stanley, an estimated $2.39M sold.
Based on aggregated 13F filings for Q3 2020.